Influence of Corneal Biomechanical Properties on Myopia Control

Sponsor
Buddhist Tzu Chi General Hospital (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05090592
Collaborator
(none)
100
1
24
4.2

Study Details

Study Description

Brief Summary

to analyze the changes in corneal biomechanics of myopic children with different treatment (low concentration atropine eye drops and orthokeratology) and explore the possible mechanism of myopia control

Condition or Disease Intervention/Treatment Phase
  • Device: orthokeratology
  • Drug: 0.01 atropine

Detailed Description

High myopia is accompanied by excessive growth of eyeball, which leads to many complications. Myopia control is a great concern of the government and ophthalmologists worldwide.

Atropine eye drops is used clinically to control the progression of myopia. In recent years, low dose Atropine eye drops (0.01%, 0.05% and 0.1%) have been proven to be effective in slowing growth of eyeball. With less negative effects, these eye drops have been widely used for school children in Taiwan. Orthokeratology is another effective tool to control myopia, and long-term wearing of Ortho-k lens can inhibit the speed of eyeball growth, it is the most useful optical treatment for myopia control.

The Corvis® ST is a combination of an air pulse tonometer with an ultra-high-speed Scheimpflug camera. The movement of the cornea is mainly influenced by three factors which can be measured by the instrument:

Intraocular pressure (IOP),biomechanical properties of the cornea and corneal thickness. The relationship between adult corneal biomechanics and refractive error has been noted in recent years. Previous studies pointed out that corneal biomechanics analyzer (Corvis ST) can measure the deformation process of the cornea and the biomechanics parameters. These literature found that the corneas of myopic patients, esp. high myopic, have larger corneal deformation in biomechanics analysis and revealed that the corneal stiffness of myopia patients was lower. There are still few discussions about the effect of orthokeratology on corneal biomechanics and there is no research focused on the change of corneal biomechanics of low-concentration atropine user which is worthy of our further exploration.

In this study, the investigators hope to analyze the changes in corneal biomechanics of myopic children with different treatment (low concentration atropine eye drops and orthokeratology) and explore the possible mechanism of myopia control.

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Influence of Corneal Biomechanical Properties on Myopia Reduction and Axial Elongation in Children Using Orthokeratology and 0.01% Atropine
Actual Study Start Date :
Jan 1, 2021
Anticipated Primary Completion Date :
Jul 30, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
myopic children

Myopic children use overnight orthokeratology or 0.01% atropine eye drop per night for myopia control

Device: orthokeratology
orthokeratology wearing for myopia control

Drug: 0.01 atropine
0.01% atropine eye drop prevent myopic progression

Outcome Measures

Primary Outcome Measures

  1. changes of the intraocular pressure in myopic children with different treatment [from the date of starting treatment, the IOP was measured 1 week, 1month and every 3 months up to 24 months.]

    the investigators measure the intraocular pressure(IOP, mmHg) of myopic children with different treatment (low concentration atropine eye drops and orthokeratology)

  2. changes of the visual acuity in myopic children with different treatment [from the date of starting treatment, the visual acuity was measured 1 week, 1month and every 3 months up to 24 months.]

    the investigators measure the visual acuity of myopic children with different treatment (low concentration atropine eye drops and orthokeratology).

  3. changes of the central corneal thickness in myopic children with different treatment [from the date of starting treatment, the central corneal thickness was measured 1 week, 1month and every 3 months up to 24 months.]

    the the investigators measure the central corneal thickness(CCT, micrometer, ㎛) of myopic children with different treatment (low concentration atropine eye drops and orthokeratology) by Corvis ST machine

  4. changes of the corneal biomechanics index in myopic children with different treatment [from the date of starting treatment, the corneal biomechanics index was measured 1 week, 1month and every 3 months up to 24 months.]

    the the investigators measure the corneal biomechanics index (CBI) of myopic children with different treatment (low concentration atropine eye drops and orthokeratology) by Corvis ST machine

  5. changes of the stress-strain index in myopic children with different treatment [from the date of starting treatment, the stress-strain index (SSI) was measured 1 week, 1month and every 3 months up to 24 months.]

    the the investigators measure the stress-strain index (SSI) of myopic children with different treatment (low concentration atropine eye drops and orthokeratology) by Corvis ST machine

Secondary Outcome Measures

  1. changes of axial length in myopic children with different treatment [from the date of starting treatment, the axial length was measured, then repeat measure were performed every 6 months up to 24 months]

    the investigators measure the axial length(mm) of eyeball of myopic children with different treatment (low concentration atropine eye drops and orthokeratology).

Eligibility Criteria

Criteria

Ages Eligible for Study:
8 Years to 20 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • myopia (<-1D)

  • received Orthokeratology or 0.01% atropine for myopia control

  • regular follow-up

Exclusion Criteria:
  • ocular surface disease( dry eye, keratoconus..)

  • allergy to orthokeratology or atropine

  • received eye surgery

  • strabismus

  • premature birth

Contacts and Locations

Locations

Site City State Country Postal Code
1 Yu-Teng Lai Yilan Ilan County Taiwan 265

Sponsors and Collaborators

  • Buddhist Tzu Chi General Hospital

Investigators

  • Study Director: Cheng-Jen Chiu, Doctor, Tzu Chi genral hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Buddhist Tzu Chi General Hospital
ClinicalTrials.gov Identifier:
NCT05090592
Other Study ID Numbers:
  • Buddhist TCGH
First Posted:
Oct 25, 2021
Last Update Posted:
Oct 25, 2021
Last Verified:
Sep 1, 2021
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 25, 2021